Summit Therapeutics Inc. (SMMT) NASDAQ
14.86
-0.85(-5.41%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
14.86
-0.85(-5.41%)
Currency In USD
Address
One Broadway
Cambridge, MA 02142
United States of America (the)
Phone
617 514 7149
Website
Sector
Healthcare
Industry
Biotechnology
Employees
159
First IPO Date
March 05, 2015
| Name | Title | Pay | Year Born |
| Robert W. Duggan | Co-CEO & Executive Chairman | 172,376 | 1945 |
| Mahkam Zanganeh | Co-CEO, President & Director | 1.03M | 1970 |
| Manmeet Singh Soni | Chief Operating Officer, Chief Financial Officer & Director | 1.03M | 1978 |
| Robert LaCaze | Chief Commercial Officer | 0 | N/A |
| Nathan LiaBraaten | Senior Director of Investor Relations | 0 | N/A |
| Kay Elizabeth Davies | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor | 0 | 1951 |
| Allen S. Yang | Head of R&D Strategy | 0 | 1968 |
| Laura Q. Chow | Senior Vice President of Clinical Development | 0 | N/A |
| Urte Gayko | Chief Regulatory, Quality & Pharmacovigilance Officer | 0 | 1971 |
| Wang Clow Fong | Chief Biometrics Officer | 0 | 1958 |
| Bhaskar Anand | Chief Accounting Officer | 0 | 1977 |
| Dave Gancarz | Chief Business & Strategy Officer | 0 | N/A |
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.